Please upgrade your browser.
The Angiogenesis Foundation will release two new white papers, in conjunction with the American Society of Clinical Oncology (ASCO) Annual Meeting, which address the needs, challenges, and proposed solutions to improve outcomes in two of the top ten most common cancers in the United States: metastatic colorectal cancer (mCRC) and renal cell carcinoma (RCC), also known as kidney cancer.
Scandinavian workers exposed to a common industrial cleaning fluid showed higher risk for developing cancers of the liver, kidneys and cervix in a large new study.
Researchers at Dartmouth-Hitchcock Norris Cotton Cancer Center presented a poster on a phase I clinical trial of Nivolumab, a PD-1 receptor blocking antibody, being used in combination with other drugs in patients with metastatic renal cell carcinoma (mRCC) at the ASCO Annual Meeting.
Focus on colon, breast cancer drug
"Everything has shrunk," said the 62-year-old contractor from Wolcott, Connecticut, who still goes for treatment every two weeks and has regular scans to keep tabs on his progress. "Some of the tumors you can't even see."
Can statin drugs help prevent kidney cancer? This edition also includes a link to videos that will help you to learn how to take your anti-cancer drug, along with information about side effects.
Kidney Cancer Association and Conquer Cancer Foundation work together to promote and sponsor research projects.
A pre-filtered list of abstracts related to renal cell carcinoma (RCC) from the 2013 Annual Meeting of the American Society of Clinical Oncology, held this week in Chicago.
We have launched a patient registry for kidney cancer.
ASONEP is a humanized antibody that binds to and neutralizes sphingosine-1-phosphate (S1P). S1P is a bioactive lipid that has been validated as a drug target in multiple sclerosis and that has been shown to contribute to progression of several cancer types.
|Powered by NeonCRM|